Erythropoietin induces bone marrow and plasma fibroblast growth factor 23 during acute kidney injury.

@article{Toro2018ErythropoietinIB,
  title={Erythropoietin induces bone marrow and plasma fibroblast growth factor 23 during acute kidney injury.},
  author={Luis Toro and V{\'i}ctor Barrientos and Pablo T. Le{\'o}n and Macarena Rojas and Magdalena C Gonz{\'a}lez and Alvaro M Gonzalez-Ibanez and Sebasti{\'a}n E Illanes and Keigo Sugikawa and N{\'e}stor Abarz{\'u}a and C{\'e}sar Bascu{\~n}{\'a}n and Katherine Arcos and Carlos Fuentealba and Ana Mar{\'i}a Tong and Alvaro A. Elorza and Maria Eug{\^e}nia B. Pinto and Rodrigo Alzamora and Carlos Montalvo Romero and Luis Michea},
  journal={Kidney international},
  year={2018},
  volume={93 5},
  pages={1131-1141}
}
It is accepted that osteoblasts/osteocytes are the major source for circulating fibroblast growth factor 23 (FGF23). However, erythropoietic cells of bone marrow also express FGF23. The modulation of FGF23 expression in bone marrow and potential contribution to circulating FGF23 has not been well studied. Moreover, recent studies show that plasma FGF23 may… CONTINUE READING